Greensignal Bio Pharma Ltd
₹
None%
- close price
About
[
edit about
]
[
add key points
]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE -5.86 %
- ROE -20.5 %
- Face Value ₹
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -13.2% over past five years.
- Company has a low return on equity of -5.85% over last 3 years.
- Company might be capitalizing the interest cost
- Working capital days have increased from 836 days to 1,384 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|
| 27 | 30 | 29 | 13 | 28 | 13 | |
| 19 | 23 | 15 | 16 | 19 | 18 | |
| Operating Profit | 8 | 7 | 14 | -3 | 9 | -5 |
| OPM % | 31% | 23% | 49% | -22% | 31% | -37% |
| 0 | -0 | 2 | 2 | 0 | -4 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 |
| Profit before tax | 6 | 4 | 13 | -4 | 6 | -13 |
| Tax % | 37% | 29% | 24% | 2% | 16% | 19% |
| 4 | 3 | 10 | -4 | 5 | -15 | |
| EPS in Rs | 0.93 | 0.76 | 2.59 | -1.12 | 1.40 | -3.96 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -23% |
| TTM: | -53% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -308% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | -6% |
| Last Year: | -21% |
Balance Sheet
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|
| Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 |
| Reserves | 11 | 13 | 23 | 18 | 24 | 9 |
| 3 | 0 | 0 | 0 | 48 | 108 | |
| 6 | 7 | 7 | 7 | 9 | 9 | |
| Total Liabilities | 58 | 58 | 68 | 63 | 119 | 164 |
| 39 | 35 | 33 | 31 | 28 | 58 | |
| CWIP | 0 | 0 | 0 | 0 | 45 | 45 |
| Investments | 0 | 8 | 12 | 0 | 0 | 2 |
| 19 | 16 | 22 | 32 | 46 | 59 | |
| Total Assets | 58 | 58 | 68 | 63 | 119 | 164 |
Cash Flows
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|
| -1 | 12 | 4 | -11 | -2 | -26 | |
| -3 | 1 | -2 | -0 | -42 | -34 | |
| 0 | 3 | -5 | 12 | 48 | 59 | |
| Net Cash Flow | -4 | 16 | -2 | 1 | 5 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 34 | 85 | 129 | 92 | 1 |
| Inventory Days | 548 | 113 | 551 | 404 | 255 | 259 |
| Days Payable | 97 | 63 | 69 | 50 | 81 | 79 |
| Cash Conversion Cycle | 515 | 85 | 567 | 482 | 267 | 180 |
| Working Capital Days | 189 | 75 | 188 | 668 | 455 | 1,384 |
| ROCE % | 9% | 24% | -7% | 8% | -6% |
Documents
Annual reports
No data available.